TherapeuticsMD, Inc. — Director's Dealing 2020

Feb 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2020-02-03

Reporting Person: Krassan Mitchell (Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-03	Common Stock	M	105703	$0.1874	Acquired	105703	Direct
2020-02-03	Common Stock	M	194297	$0.2037	Acquired	300000	Direct
2020-02-03	Common Stock	S	300000	$2.2564	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-03	Non-Qualified Stock Option (right to buy)	$0.1874	M	105703	Disposed	2020-05-01	Common Stock (105703)	Direct
2020-02-03	Non-Qualified Stock Option (right to buy)	$0.2037	M	194297	Disposed	2020-09-01	Common Stock (194297)	Direct

Footnotes

F1: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan dated December 10, 2019 with respect to shares of common stock underlying options to purchase common stock that expire on or before September 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.285, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.